Time-resolved immune dynamics in rheumatoid arthritis under Methotrexate therapy

Abstract

Rheumatoid arthritis (RA) is characterized by immune dysregulation, including alterations in peripheral blood mononuclear cell (PBMC) populations and aberrant cytokine signaling. Methotrexate (MTX) is the preferred first-line treatment for RA, yet its precise mechanisms of action remain incompletely understood. This study employed a multi-omics strategy-combining single-cell RNA sequencing (scRNA-seq) and immunophenotyping-to identify key effector peripheral immune cells and their cellular responses in RA patients over 12 weeks of MTX treatment. In our study, MTX was associated with significant immune modulation, including the restoration of naive T and B cells and reductions in T cell memory subsets with these effects detectable as early as three weeks post-treatment. Plasmablast levels also emerged as a potential biomarker for early therapeutic response, reflecting MTX's impact on immune homeostasis. Transcriptional analysis revealed modulation of key pathways, including TNF-alpha; signaling, B cell receptor signaling, and T cell receptor-mediated apoptosis. Network analysis identified critical regulatory hubs, such as EGR1, JAK2, and SOCS1, in monocytes and CD4 memory T cells, highlighting these cell types as key mediators of MTX's effects. In conclusion, these findings advance our understanding of MTX's effects on immune cell dynamics at different stages of treatment, showing for the first time the early cellular changes leading to immune modulation in RA. Altogether, our results provide the foundation for further mechanistic investigations into MTX.

Competing Interest Statement

MaB and TP received funding from Lilly. MiB received grants from AlphaSigma. DA received grants and consulting fees from AbbVie, Amgen,Lilly, Merck, Novartis, Pfizer, Roche and Sandozand.

Footnotes

* One of the authors name was accidentally omitted in the online form of the initial submission, author added.